---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-068108"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2022-06-03T23:59:59+00:00"
generated_at: "2026-06-25T04:39:07.383580+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics CFO Thomas Reilly resigns; Richard Makara named interim CFO

## Summary
- Thomas Reilly resigns as CFO effective June 15, 2022 to pursue a new opportunity.
- Departure is not due to any dispute or disagreement with the company.
- Richard Makara, VP Head of Accounting & Controller, assumes interim CFO role.
- Makara receives 7,500 RSUs vesting at earlier of Dec 31, 2022 or new CFO appointment.
- Makara previously served as interim CFO from Dec 2019 to Oct 2020.

## SEC filing metadata
- accession: 0001104659-22-068108
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2022-06-03T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/0001104659-22-068108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/tm2217665d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-068108
- JSON: https://secwatch.observer/filing/0001104659-22-068108.json
- Plain text: https://secwatch.observer/filing/0001104659-22-068108.txt

## Key facts
- Executive change
  Richard Makara was appointed as Interim Chief Financial Officer at Tvardi Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: Effective immediately following Mr. Reilly’s departure, Richard Makara, the Company’s Vice President, Head of Accounting & Controller, will assume Mr. Reilly’s responsibilities on an interim basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/0001104659-22-068108-index.htm
- Executive change
  Thomas Reilly resigned as Chief Financial Officer at Tvardi Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On May 27, 2022, Thomas Reilly, Chief Financial Officer of Cara Therapeutics, Inc. (the “Company”), gave notice of his resignation, effective on or about June 15, 2022, to pursue a new opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/0001104659-22-068108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.